End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
135,000 KRW | -1.39% | +1.35% | -43.98% |
Mar. 21 | Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company returns high margins, thereby supporting business profitability.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an enterprise value anticipated at 3606.91 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.98% | 656M | D | ||
-4.24% | 86.85B | A- | ||
+2.76% | 40.16B | A- | ||
-16.69% | 31.28B | B- | ||
+57.86% | 25.27B | A | ||
-14.40% | 15.33B | C | ||
-9.12% | 11.96B | D+ | ||
-42.56% | 11.61B | B | ||
+6.89% | 8.83B | B+ | ||
-10.53% | 7.94B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A086900 Stock
- Ratings Medy-Tox Inc.